Abnova’s humanized antibody service starts with mouse monoclonal antibody production via mouse immunization, splenic fusion, hybridoma screening, antibody selection, and isotype determination. The selected mouse monoclonal antibody undergoes variable gene sequencing for complementarity-determining region (CDR) grafting, and if needed specificity determining residues (SDR) grating, onto the human antibody construct followed by sequence alignment and production. The humanized antibody is then characterized by a series of in vitro and in vivo assays to assure its biochemical, biophysical, and functional properties. Moreover, the Fc region of the humanized antibody is mutated to minimize antibody-dependent enhancement (ADE) immune response.
See Technology
|
|
| |
| Monoclonal Antibody Productions |
|
- Antigen Preparation
- Mouse Immunization
- Hybridoma Screening
- Antibody Selection
- Isotype Determination
|
| |
| Monoclonal Antibody Humanization |
|
- Mouse Antibody Variable Gene Sequencing
- Complementarity-Determining Region (CDR) Grafting
- Specificity Determining Residue (SDR) Grating
- Humanized Antibody Sequence Alignment
- Humanized Antibody Variant Production
|
| |
|
|
| |
| Humanized Antibody Characterizations |
|
- Protein and Peptide Mapping
- Affinity Kinetic Assay
- Binding, Inhibition, Neutralization Assays
- Cytokine, ADCC/CDC, and Toxicology Assays
- Animal Assay
|
| |
| Humanized Antibody Fc Engineering |
|
- LALAPG mutation
- LALANG mutation
|
| |
|
|
| |
| Example |
|
| COVID-19 Humanized Monoclonal Antibody (clone 7F7) |
|
|
| |
| CD3 Humanized Monoclonal Antibody |
|
|
| |
|
For any inquiry, please contact : OEM@abnova.com
